SAGE (Sage Therapeutics) EBIT per Share : $-5.89 (TTM As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics EBIT per Share?

Sage Therapeutics's EBIT per Share for the three months ended in Mar. 2025 was $-1.08. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.89.

During the past 3 years, the average EBIT per Share Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sage Therapeutics's EBIT per Share or its related term are showing as below:

SAGE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -81.1 Med: -39.3 Max: 12.8
Current: 4.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sage Therapeutics was 12.80% per year. The lowest was -81.10% per year. And the median was -39.30% per year.

SAGE's 3-Year EBIT Growth Rate is ranked worse than
55.63% of 1217 companies
in the Biotechnology industry
Industry Median: 9.3 vs SAGE: 4.90

Sage Therapeutics's EBIT for the three months ended in Mar. 2025 was $-66.94 Mil.

Sage Therapeutics EBIT per Share Historical Data

The historical data trend for Sage Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics EBIT per Share Chart

Sage Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

11.77

-7.86

-9.22

-9.13

-6.76

Sage Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial															-1.96	-1.84	-1.66	-1.31	-1.08

Sage Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sage Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-410.516	/	60.766
=	-6.76

Sage Therapeutics's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-66.942	/	61.858
=	-1.08

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.89

Sage Therapeutics (NAS:SAGE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sage Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

SG7:Germany

Address

55 Cambridge Parkway, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Executives

Elizabeth Barrett	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas	director, officer: See Remarks	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault	officer: Chief Medical Officer	C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi	officer: Chief Commercial Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates	director	88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud	officer: Chief Scientific Officer	215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan	officer: Chief Business Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook	officer: General Counsel	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi	officer: See Remarks	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035